Get startedLog in
    Picture of Basilea Pharmaceutica AG, Allschwil logo

    BSLN — Basilea Pharmaceutica AG, Allschwil News Story

    0.000.00%
    ch flag iconLast trade - 00:00
    HealthcareAdventurousMid CapHigh Flyer
    All News

    Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln

    Picture of Basilea Pharmaceutica AG, Allschwil logoBasilea Pharmaceutica AG, Allschwil
    27/10/2026 06:04
    BRIEF-Basilea Expects 2026 Operating Profit Of CHF 115 Mln
    Oct 27 (Reuters) - BASILEA PHARMACEUTICA AG, ALLSCHWIL BSLN.S:
    • RAISES FULL-YEAR GUIDANCE 2026 AND FINANCIAL TARGET FOR “AGENDA 2030” AND PROVIDES UPDATES ON LATE-STAGE CLINICAL PROGRAMS
    • 2026 OPERATING PROFIT EXPECTED TO REACH CHF 115 MILLION
    • RAISES FINANCIAL GUIDANCE FOR FY2026 AND CASH FLOW TARGET FOR 2026-2030
    • FY2026 RESEARCH AND DEVELOPMENT EXPENSES GUIDANCE CHF 125 MILLION; OPERATING PROFIT GUIDANCE CHF 115 MILLION
    • OUTLOOK 2026: EXPECTS TOTAL REVENUE AROUND CHF 310 MILLION
    Source text: ID:nGNE5F04qM
    Further company coverage: BSLN.S

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 587785269;))

    Recent news on Basilea Pharmaceutica AG, Allschwil

    See all news